[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-001", "question": "A 27-year-old G1P0 at 9 weeks' gestation presents with intractable nausea and vomiting, 7-kg weight loss, new-onset jaundice, and confusion over 3 days. She has no prior liver disease or alcohol use. Vitals: T 37.2°C, HR 122, BP 100/62, RR 18, SpO2 98% RA. Exam: scleral icterus, moderate right upper quadrant tenderness without rebound, asterixis. Labs: Na 132, K 3.1, bicarbonate 19, creatinine 1.2 mg/dL (baseline 0.6), AST 545 U/L, ALT 510 U/L, ALP 225 U/L, total bilirubin 12.4 mg/dL (direct 8.1), INR 2.6, ammonia 102 µmol/L, β-hCG markedly elevated for gestational age, thyroid studies: TSH low, free T4 and T3 mildly elevated. Abdominal ultrasound: single live intrauterine pregnancy, normal hepatic and portal vasculature, no biliary dilation, mild fatty liver change. Viral hepatitis serologies and autoimmune markers are pending. She is receiving IV fluids and antiemetics but continues to deteriorate neurologically. Which of the following is the most appropriate immediate next management step?", "options": ["Administer high-dose IV methylprednisolone and defer pregnancy decisions until serologies return", "Urgently proceed with uterine evacuation and initiate N-acetylcysteine infusion", "Start high-dose IV thiamine and parenteral nutrition while continuing pregnancy", "List for emergent liver transplantation without altering pregnancy status", "Administer propylthiouracil and beta-blockers to treat probable gestational thyrotoxicosis and reassess"], "answer": "B", "answer_index": 1, "explanation": "This presentation is most consistent with hyperemesis gravidarum-associated acute liver failure with encephalopathy and coagulopathy; maternal survival takes precedence, and rapid uterine evacuation plus N-acetylcysteine offers the best chance to reverse fulminant hepatic injury. Steroids (A) address autoimmune hepatitis, which is unconfirmed and too slow. Thiamine and nutrition (C) are supportive but insufficient in fulminant failure with encephalopathy. Immediate transplantation listing (D) may be needed but should follow rapid removal of the precipitating factor. Treating mild gestational thyrotoxicosis alone (E) will not address the primary life-threatening hepatic process.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with severe hyperemesis gravidarum that has progressed to acute liver failure, as evidenced by jaundice, elevated liver enzymes, coagulopathy (INR 2.6), and hepatic encephalopathy (confusion and asterixis). The markedly elevated β-hCG for gestational age, along with the clinical picture, is highly concerning for hyperemesis gravidarum complicated by acute liver failure.\n\nThe key findings include:\n- Intractable nausea and vomiting with significant weight loss\n- Acute liver failure (elevated transaminases, hyperbilirubinemia, coagulopathy)\n- Hepatic encephalopathy (confusion, asterixis)\n- Markedly elevated β-hCG\n- Mild thyroid abnormalities (likely secondary to HCG effects)\n- Ultrasound showing mild fatty liver changes\n\nThis presentation is consistent with hyperemesis gravidarum progressing to acute liver failure, which can be fatal without prompt intervention. The patient is deteriorating neurologically despite supportive care.\n\nIn this scenario, the most appropriate immediate management is to terminate the pregnancy, as the liver failure is directly related to the pregnancy and is life-threatening. Additionally, N-acetylcysteine has been shown to improve outcomes in acute liver failure.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-002", "question": "A 63-year-old man with long-standing hypertension and ischemic cardiomyopathy (EF 30%) presents with acute right hemiplegia and aphasia 45 minutes after symptom onset. NIHSS is 18. Noncontrast CT head shows no hemorrhage. CT angiography shows left M1 occlusion with favorable collaterals; CT perfusion suggests a large salvageable penumbra. ECG shows sinus rhythm with frequent PVCs. High-sensitivity troponin is mildly elevated and flat on serial testing. You plan IV thrombolysis and urgent mechanical thrombectomy. Which of the following additional acute management steps is most appropriate?", "options": ["Initiate IV unfractionated heparin infusion before mechanical thrombectomy due to high cardioembolic risk", "Administer IV labetalol to reduce blood pressure to <140/90 mm Hg prior to thrombolysis", "Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis", "Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis", "Place an intra-aortic balloon pump preemptively to support cerebral perfusion during thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "The correct step is to start high-intensity statin immediately and delay antiplatelets until 24 hours after thrombolysis and repeat imaging, per acute ischemic stroke guidelines. Heparin before thrombectomy (A) increases hemorrhagic risk with no proven benefit. Lowering BP below 140/90 (B) before tPA is too aggressive and can worsen cerebral perfusion; only treat if >185/110 to that threshold. Dual antiplatelets immediately after tPA (D) markedly increases hemorrhage risk. Intra-aortic balloon pump (E) has no role in this setting and carries procedural risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "For this acute ischemic stroke case with planned IV thrombolysis and mechanical thrombectomy, I need to identify the most appropriate additional management step.\n\nOption A (IV heparin) is contraindicated before thrombectomy in a patient receiving thrombolysis due to increased bleeding risk.\n\nOption B (IV labetalol to reduce BP <140/90) aligns with guidelines for blood pressure management before thrombolysis. Current guidelines recommend BP <185/110 mmHg before thrombolysis, making this reasonable.\n\nOption C (high-dose statin and delay antiplatelet therapy) follows standard practice. High-dose statins are recommended acutely, and antiplatelet therapy should be delayed for 24 hours after thrombolysis to reduce bleeding risk.\n\nOption D (dual antiplatelet therapy immediately after thrombolysis) is contraindicated as it increases bleeding risk when given immediately after thrombolysis.\n\nOption E (intra-aortic balloon pump) is not standard practice for stroke management and carries significant risks without proven benefit.\n\nThe most appropriate option is C, as it follows evidence-based guidelines for acute stroke management with thrombolysis.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-003", "question": "A 34-year-old woman with SLE (malar rash, arthritis, class III lupus nephritis on biopsy) on mycophenolate and low-dose prednisone presents with 3 months of progressive exertional dyspnea and dry cough. She has no smoking history. Vitals: HR 96, BP 112/70, RR 18, SpO2 94% RA. Exam: fine bibasilar crackles, no peripheral edema. Labs: creatinine 1.0 mg/dL, ANA 1:640 homogeneous, anti-dsDNA mildly elevated, complements low, ESR 18 mm/hr, CRP 2 mg/L. PFTs: FVC 65% predicted, FEV1/FVC 0.82, DLCO 40% predicted. HRCT: diffuse ground-glass opacities with scattered areas of consolidation and traction bronchiectasis, predominantly in lower lobes, no honeycombing. BAL: lymphocytic predominance, cultures negative. Echocardiogram: normal LV function, PASP 30 mm Hg. Which of the following is the most appropriate next step in management?", "options": ["Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics", "Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation", "Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP", "Add rituximab while continuing mycophenolate at the same dose", "Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD"], "answer": "E", "answer_index": 4, "explanation": "This is SLE-associated progressive fibrosing interstitial lung disease with traction bronchiectasis and physiologic restriction despite immunosuppression; nintedanib has evidence for slowing decline in progressive fibrosing ILDs, including CTD-ILD. Blind escalation of steroids/mycophenolate (A) risks toxicity without clear additional benefit. Routine upfront lung transplant listing (B) is premature. Lung biopsy (C) is high risk and unlikely to alter management given established CTD-ILD pattern. Rituximab (D) can be considered, but antifibrotic therapy specifically targets the progressive fibrosing phenotype and is strongly indicated here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To determine the most appropriate next step in management for this patient, I'll analyze the clinical presentation and findings.\n\nThe patient has:\n- Known SLE with active disease (elevated anti-dsDNA, low complements)\n- Progressive exertional dyspnea and dry cough for 3 months\n- Restrictive pattern on PFTs with significantly reduced DLCO\n- HRCT showing ground-glass opacities, consolidation, and traction bronchiectasis\n- Lymphocytic predominance on BAL with negative cultures\n- Normal cardiac function\n\nThese findings are consistent with an interstitial lung disease (ILD) related to SLE. The pattern suggests either nonspecific interstitial pneumonia (NSIP) or organizing pneumonia, both of which can occur in SLE.\n\nEvaluating the options:\nA. Escalating immunosuppression with high-dose steroids is reasonable for acute/subacute ILD in SLE, especially with evidence of active disease.\n\nB. Cyclophosphamide is used for severe manifestations, but immediate lung transplant listing is premature without trying adequate immunosuppression first.\n\nC. Surgical lung biopsy carries risks and may not change management significantly since both NSIP and organizing pneumonia respond to immunosuppression.\n\nD. Rituximab is effective for refractory SLE-ILD but would typically be considered after failure of first-line therapies.\n\nE. Nintedanib is approved for progressive fibrosing ILD, but immunosuppression should be optimized first for SLE-ILD.\n\nGiven the progressive symptoms, active SLE, and ILD findings, intensifying immunosuppression is the most appropriate next step before considering more invasive procedures or advanced therapies.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-004", "question": "A 51-year-old woman with poorly controlled type 2 diabetes and prior pelvic radiation for cervical cancer presents with 5 days of fever, worsening lower abdominal pain, and foul vaginal discharge. She is hypotensive and tachycardic. Exam: diffuse lower abdominal tenderness with guarding, necrotic friable tissue at the posterior vaginal fornix with gas bubbles and crepitus extending toward the rectovaginal septum. Labs: WBC 19,000/µL, lactate 4.5 mmol/L, creatinine 2.1 mg/dL. CT abdomen/pelvis with contrast: extensive gas in the pelvis tracking along fascial planes into the perineum, no discrete drainable collection, suspected uterine and vaginal wall necrosis. Blood cultures are drawn, and broad-spectrum IV antibiotics and aggressive fluids are started. Which is the most appropriate next step?", "options": ["Urgent total abdominal hysterectomy with wide radical debridement of necrotic pelvic and perineal tissue", "Percutaneous CT-guided drainage of gas-containing pelvic spaces plus continued maximal antibiotics", "Hyperbaric oxygen therapy as a temporizing measure before any surgical intervention", "Emergent exploratory laparotomy limited to diagnostic assessment and peritoneal lavage", "Conservative management with antibiotics and close ICU monitoring to avoid worsening radiation injury"], "answer": "A", "answer_index": 0, "explanation": "The clinical picture is necrotizing pelvic soft tissue infection (type I Fournier-like process) involving uterus and vagina in a radiated field, requiring immediate radical surgical debridement including hysterectomy. Percutaneous drainage (B) is inadequate for necrotizing fasciitis. Hyperbaric oxygen (C) may be adjunctive but never replaces urgent debridement. Exploratory laparotomy without aggressive debridement (D) fails to control source. Conservative management (E) carries an almost universally fatal risk in necrotizing infections.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with clinical features highly concerning for necrotizing soft tissue infection of the pelvis/perineum, likely necrotizing fasciitis. The key findings include:\n\n- Poorly controlled diabetes (risk factor)\n- Prior pelvic radiation (risk factor)\n- Hypotension and tachycardia (systemic inflammatory response)\n- Necrotic tissue with gas bubbles and crepitus (classic finding in necrotizing infection)\n- Elevated WBC and lactate (indicating severe infection and tissue hypoperfusion)\n- CT showing gas tracking along fascial planes (pathognomonic for necrotizing fasciitis)\n\nNecrotizing soft tissue infections are surgical emergencies requiring immediate and aggressive debridement of all necrotic tissue. The mortality rate increases significantly with delays in surgical intervention.\n\nOption A (urgent total hysterectomy with wide radical debridement) is the most appropriate management. This addresses the source of infection and removes all necrotic tissue.\n\nOption B (percutaneous drainage) is inadequate for necrotizing infections, which require open surgical debridement.\n\nOption C (hyperbaric oxygen) may be an adjunctive therapy but should never delay surgical debridement.\n\nOption D (exploratory laparotomy limited to diagnostic assessment) is insufficient as it doesn't include therapeutic debridement.\n\nOption E (conservative management) would be inappropriate and potentially fatal given the clear evidence of necrotizing infection.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-005", "question": "A 76-year-old man with permanent atrial fibrillation on apixaban, CKD stage 3b, and prior TIA undergoes TAVR for symptomatic severe aortic stenosis. Preprocedure echo: EF 55%, no intracardiac thrombus, moderate MAC, mild-moderate MR. Postprocedure, he develops acute severe dyspnea and hypotension 2 hours later. Echo: hyperdynamic LV with near-complete mid-cavity obliteration in systole, peak LVOT gradient 80 mm Hg, systolic anterior motion (SAM) of the mitral valve, severe MR, intact TAVR function. Which of the following is the most appropriate immediate management?", "options": ["Start high-dose IV furosemide and nitroprusside to rapidly reduce preload and afterload", "Administer aggressive IV crystalloids and start a phenylephrine infusion while reducing inotropes", "Urgently return to the cath lab for balloon post-dilatation of the TAVR prosthesis", "Begin IV milrinone infusion to augment contractility and improve forward flow", "Perform emergent surgical myectomy with mitral valve repair"], "answer": "B", "answer_index": 1, "explanation": "This is dynamic LVOT obstruction with SAM and severe MR precipitated by TAVR and low preload; management mirrors hypertrophic obstructive physiology-volume expansion and pure alpha-agonist (phenylephrine) to increase afterload while avoiding inotropes. Diuresis and vasodilators (A) and inotropes (D) worsen obstruction. Post-dilatation of the valve (C) is not indicated as prosthetic function is normal. Emergent surgery (E) is reserved for refractory cases after optimal medical hemodynamic management has failed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient is experiencing dynamic left ventricular outflow tract (LVOT) obstruction with systolic anterior motion (SAM) of the mitral valve after TAVR. This is evidenced by the hyperdynamic LV with mid-cavity obliteration, high LVOT gradient, SAM, and severe MR. The TAVR itself is functioning properly.\n\nThis condition requires management strategies that reduce contractility and increase preload and afterload:\n\nA. High-dose furosemide and nitroprusside would worsen the condition by reducing preload and afterload, which would exacerbate LVOT obstruction.\n\nB. IV fluids and phenylephrine are the correct approach. Increasing preload with fluids and increasing afterload with phenylephrine helps reduce the LVOT gradient. Reducing inotropes (if present) decreases contractility, which also helps reduce obstruction.\n\nC. Balloon post-dilation is not indicated as the TAVR is functioning properly.\n\nD. Milrinone would worsen the condition by increasing contractility and reducing afterload.\n\nE. Surgical myectomy is not an immediate management option and would be considered only if medical management fails.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-006", "question": "A 42-year-old man who injects drugs presents with 10 days of fever, severe back pain, and new right leg weakness. Vitals: T 38.8°C, HR 108, BP 122/74. Exam: midline lumbar tenderness, right leg 3/5 strength with hyperreflexia, left leg 5/5, intact sensation, no bowel/bladder symptoms. Labs: WBC 15,000/µL, ESR 96 mm/hr, CRP 120 mg/L. Blood cultures: MRSA in 2/2 sets. MRI lumbar spine with contrast: dorsal epidural collection L2-L4 with significant canal compromise and enhancement consistent with epidural abscess, plus adjacent vertebral osteomyelitis; no discrete psoas abscess. He is started on IV vancomycin. Neurosurgery feels surgery is high risk due to severe cardiomyopathy (EF 20%) and active drug use, recommending medical therapy unless deterioration. What is the most appropriate next step?", "options": ["Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks", "Add rifampin to vancomycin to enhance penetration into epidural space and bone", "Perform urgent surgical decompression and drainage despite high perioperative risk", "Switch to daptomycin plus ceftaroline to provide broader MRSA coverage", "Place percutaneous CT-guided drain into the epidural collection to avoid open surgery"], "answer": "C", "answer_index": 2, "explanation": "He has spinal epidural abscess with evolving motor deficit and significant canal compromise; urgent surgical decompression and drainage is indicated despite elevated operative risk, as delay risks permanent paralysis. Medical therapy alone (A, B, D) is inadequate once neurologic deficits are present. Percutaneous drainage (E) is not appropriate for epidural abscess causing cord compression, as it rarely achieves effective decompression or safe access to the epidural space.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the management of spinal epidural abscess with vertebral osteomyelitis caused by MRSA in a patient with significant comorbidities.\n\nThe patient has:\n- Epidural abscess with neurological deficit (right leg weakness)\n- MRSA bacteremia\n- Vertebral osteomyelitis\n- High surgical risk due to cardiomyopathy (EF 20%) and active drug use\n\nKey considerations:\n1. Spinal epidural abscess with neurological deficits typically requires surgical intervention\n2. This patient has significant surgical risk factors\n3. The neurological deficit is not complete (partial weakness) and there are no bowel/bladder symptoms\n4. Medical therapy alone may be considered in select high-risk cases with close monitoring\n\nAnalyzing the options:\nA. Vancomycin alone is appropriate for MRSA, but may not be sufficient given the neurological deficit\nB. Adding rifampin can improve penetration into biofilms and bone, potentially enhancing efficacy\nC. Urgent surgery would be indicated for progressive deficits but carries very high risk in this patient\nD. Switching antibiotics doesn't address the fundamental issue and isn't supported by evidence\nE. Percutaneous drainage is not typically feasible for epidural abscesses due to anatomical constraints\n\nGiven the presence of neurological deficit but high surgical risk, the best approach is to optimize medical therapy while closely monitoring for deterioration. Adding rifampin to vancomycin improves bone and biofilm penetration.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-007", "question": "A 31-year-old woman presents with severe headaches, transient visual obscurations, and pulsatile tinnitus 6 months postpartum. She has gained 20 kg during and after pregnancy. BMI is 38 kg/m². Exam: bilateral papilledema, full strength, no focal deficits. MRI brain with and without contrast is normal. MRV shows smooth tapering and non-visualization of the terminal right transverse sinus with small caliber sigmoid sinus and jugular bulb; the left transverse sinus is dominant and widely patent. Lumbar puncture: opening pressure 34 cm H₂O, normal CSF studies. She is started on acetazolamide and advised weight loss but continues to have progressive visual field loss on serial perimetry over 8 weeks. What is the most appropriate next step in management?", "options": ["Place a ventriculoperitoneal shunt to lower intracranial pressure", "Perform right transverse sinus stenting across the narrowed segment", "Initiate high-dose oral topiramate instead of acetazolamide", "Perform optic nerve sheath fenestration to protect vision", "Start therapeutic anticoagulation for presumed chronic venous sinus thrombosis"], "answer": "D", "answer_index": 3, "explanation": "The patient has idiopathic intracranial hypertension with rapidly progressive visual loss despite maximal medical therapy; optic nerve sheath fenestration is the preferred intervention to promptly protect vision. VP shunting (A) is an option but has higher long-term failure and complication rates and is usually considered after or when ONSF is not feasible. Transverse sinus stenting (B) is usually reserved for documented significant pressure gradients and bilateral or dominant-sided stenosis; here the right sinus is small and nondominant. Topiramate (C) is an adjunct but insufficient alone given progressive visual decline. Anticoagulation (E) is not indicated without imaging evidence of thrombosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "I'll analyze this case of idiopathic intracranial hypertension (IIH) with progressive visual field loss despite medical management.\n\nThe patient presents with:\n- Classic IIH symptoms: headaches, transient visual obscurations, pulsatile tinnitus\n- Risk factors: female, obesity, recent pregnancy\n- Papilledema with elevated opening pressure (34 cm H₂O)\n- Normal MRI and CSF studies\n- MRV showing narrowing of right transverse sinus (likely secondary to elevated ICP)\n- Progressive visual field loss despite acetazolamide and weight loss advice\n\nThe key concern is the progressive visual field loss despite 8 weeks of medical therapy, indicating treatment failure and risk of permanent vision loss.\n\nManagement options:\n- VP shunt: Effective but invasive with complications\n- Transverse sinus stenting: Addresses the venous outflow obstruction\n- Topiramate: Another medical therapy but unlikely to work if acetazolamide failed\n- Optic nerve sheath fenestration: Surgical procedure to protect vision when medical therapy fails\n- Anticoagulation: Not indicated as this is not a thrombosis but a stenosis\n\nGiven the progressive visual loss despite medical therapy, a surgical intervention is needed. Optic nerve sheath fenestration is specifically indicated to protect vision in medically refractory IIH.\n\nThe answer is (D)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-008", "question": "A 29-year-old woman with a history of two early first-trimester miscarriages and one unexplained fetal demise at 28 weeks presents for preconception counseling. She has livedo reticularis and episodes of digital ischemia in cold weather. Labs: platelets 110,000/µL, hemoglobin 11.5 g/dL, creatinine 0.9 mg/dL. Coagulation profile is normal. aPTT is mildly prolonged. Lupus anticoagulant is repeatedly positive; anticardiolipin IgG and anti-β2-glycoprotein I IgG are high-titer on two occasions 12 weeks apart. She has no personal history of venous or arterial thrombosis. Which of the following is the most appropriate pregnancy management plan?", "options": ["Low-dose aspirin alone starting preconception, escalate to prophylactic LMWH only if thrombosis occurs", "Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum", "Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery", "Low-dose aspirin only during pregnancy, with postpartum prophylactic LMWH for 6 weeks", "No anticoagulation unless she develops hypertensive disorders of pregnancy"], "answer": "B", "answer_index": 1, "explanation": "She meets criteria for high-risk obstetric antiphospholipid syndrome with recurrent pregnancy loss and triple-positive aPL; therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and 6 weeks postpartum provides optimal maternal and fetal protection. Aspirin alone (A, D, E) is inadequate in high-risk APS. Prophylactic-dose LMWH (C) may be used in lower-risk obstetric APS but is insufficient here given triple positivity and prior late fetal loss and thrombocytopenia suggestive of high thrombotic risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the most appropriate pregnancy management plan for this patient, I need to analyze her clinical presentation and risk factors.\n\nThe patient has:\n- History of recurrent pregnancy loss (two early miscarriages and one late fetal demise)\n- Livedo reticularis and digital ischemia in cold weather\n- Mild thrombocytopenia (110,000/µL)\n- Prolonged aPTT\n- Repeatedly positive lupus anticoagulant and high-titer anticardiolipin and anti-β2-glycoprotein I antibodies\n- No history of venous or arterial thrombosis\n\nThis clinical picture is consistent with antiphospholipid syndrome (APS), specifically obstetric APS given her pregnancy complications without prior thrombosis.\n\nFor women with obstetric APS and recurrent pregnancy loss, the standard of care is combination therapy with:\n- Low-dose aspirin (to improve placental perfusion)\n- Prophylactic-dose low molecular weight heparin (LMWH) (to prevent thrombosis)\n\nThis combination should be started as early as possible (at conception or positive pregnancy test) and the LMWH should be continued until delivery. The aspirin is typically continued throughout pregnancy.\n\nOption C (Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery) aligns with current guidelines for managing obstetric APS.\n\nOption A is insufficient for obstetric APS.\nOption B (therapeutic-dose LMWH) would be appropriate for patients with prior thrombosis, which this patient doesn't have.\nOption D is insufficient for obstetric APS.\nOption E is inappropriate given her clear diagnosis of APS.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-009", "question": "A 55-year-old man from a region endemic for Lyme disease presents with 1 week of rapidly progressive bilateral leg weakness and numbness ascending from the feet, severe radicular pain, and new urinary retention. He was treated with oral doxycycline 3 weeks ago for erythema migrans following a hiking trip. Exam: symmetric lower extremity weakness 3/5 proximally and distally, hyperreflexia with bilateral Babinski signs, decreased pinprick below T10, preserved vibration sense in toes, and saddle hypesthesia. Cranial nerves are normal. MRI spine with contrast: multifocal enhancing lesions in the thoracic cord with associated leptomeningeal enhancement; no compressive lesion. CSF: WBC 220/µL (80% lymphocytes), protein 120 mg/dL, glucose 45 mg/dL (serum 90), oligoclonal bands present; CSF Lyme antibody index is elevated. HIV, syphilis, and TB tests are negative. What is the most appropriate treatment?", "options": ["High-dose IV methylprednisolone alone for presumed idiopathic transverse myelitis", "IV ceftriaxone 2 g daily for 4 weeks without steroids", "IV ceftriaxone 2 g daily plus high-dose IV methylprednisolone", "Oral doxycycline 100 mg BID for 28 days plus high-dose oral prednisone taper", "Plasma exchange for 5-7 sessions followed by IV ceftriaxone"], "answer": "B", "answer_index": 1, "explanation": "This is Lyme neuroborreliosis with meningomyelitis confirmed by elevated CSF Lyme antibody index and appropriate clinical picture; standard treatment is prolonged IV ceftriaxone without routine adjunctive steroids. Steroids alone (A) are inappropriate and may worsen infection. Adding high-dose steroids to antibiotics (C) has no proven benefit and may be harmful. Oral doxycycline (D) is inadequate for CNS parenchymal involvement. Plasma exchange (E) is used in severe autoimmune demyelination (e.g., NMO, ADEM) and is not indicated here once Lyme is confirmed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to analyze the clinical presentation and diagnostic findings.\n\nThe patient has:\n- Recent history of erythema migrans (pathognomonic for Lyme disease)\n- Prior doxycycline treatment for early Lyme disease\n- Current presentation with rapidly progressive bilateral ascending weakness, sensory changes, and urinary retention\n- MRI showing multifocal enhancing lesions in thoracic cord with leptomeningeal enhancement\n- CSF showing lymphocytic pleocytosis, elevated protein, normal glucose, oligoclonal bands\n- Elevated CSF Lyme antibody index\n\nThis presentation is consistent with Lyme neuroborreliosis affecting the spinal cord (Lyme myelitis). Despite previous treatment with oral doxycycline for early Lyme disease, the patient has developed neurologic manifestations.\n\nFor Lyme disease with CNS involvement (neuroborreliosis):\n- IV ceftriaxone is the preferred treatment\n- The inflammatory component may benefit from concurrent corticosteroids\n- The neurological symptoms are severe and rapidly progressive\n\nOption C (IV ceftriaxone plus high-dose IV methylprednisolone) addresses both the infection and the inflammatory component of Lyme neuroborreliosis.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-010", "question": "A 48-year-old woman with seropositive rheumatoid arthritis (RF and anti-CCP positive) on methotrexate and adalimumab presents with subacute dyspnea and nonproductive cough. She has never smoked. Vitals: HR 104, BP 118/70, RR 22, SpO2 91% RA. Exam: fine bibasilar crackles, no wheezing, active small-joint synovitis. PFTs: FVC 58% predicted, FEV1/FVC 0.86, DLCO 35% predicted. HRCT: basilar-predominant reticulation, traction bronchiectasis, and patchy subpleural honeycombing consistent with usual interstitial pneumonia (UIP); no nodules or pleural effusions. Which of the following is the most appropriate disease-modifying management change?", "options": ["Continue methotrexate and adalimumab and add low-dose prednisone", "Discontinue methotrexate and switch adalimumab to rituximab", "Stop adalimumab and start tocilizumab while continuing methotrexate", "Continue current RA regimen and initiate mycophenolate mofetil for lung disease", "Add nintedanib while continuing methotrexate and adalimumab unchanged"], "answer": "B", "answer_index": 1, "explanation": "She has RA-associated ILD with a UIP pattern, in which methotrexate and TNF inhibitors are relatively contraindicated due to concerns for ILD progression; rituximab is preferred as an RA biologic in ILD. Continuing MTX/TNF with steroids (A) risks worsening lung fibrosis. Tocilizumab (C) has less data and does not address TNF-risk concerns. Adding mycophenolate (D) without removing potential pulmonary offenders is suboptimal. Nintedanib (E) may be beneficial in progressive fibrosing RA-ILD, but first-line is to remove MTX/TNF and choose an ILD-favorable biologic such as rituximab.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the patient's presentation and the most appropriate management change for her condition.\n\nThe patient has:\n- Seropositive rheumatoid arthritis on methotrexate and adalimumab\n- New respiratory symptoms (dyspnea, cough)\n- Reduced oxygen saturation (91%)\n- Restrictive pattern on PFTs with severely reduced DLCO\n- HRCT showing UIP pattern with honeycombing\n\nThis presentation is consistent with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with a UIP pattern, which has a poor prognosis.\n\nKey considerations:\n1. Methotrexate can cause pneumonitis but typically presents acutely and with ground-glass opacities, not UIP pattern\n2. TNF inhibitors like adalimumab have been associated with worsening or development of ILD in some cases\n3. Rituximab has shown benefit in RA-ILD in some studies\n4. Nintedanib is FDA-approved for progressive fibrosing ILD, including RA-ILD\n5. Tocilizumab has mixed evidence for RA-ILD\n\nGiven the UIP pattern with honeycombing (indicating established fibrosis) and the patient's current medications:\n- Option B (switching to rituximab and stopping methotrexate) is appropriate as rituximab may help both the RA and the ILD\n- Option E (adding nintedanib) would be reasonable for progressive fibrosis but doesn't address the potential contribution of adalimumab to the ILD\n- Continuing adalimumab (options A, D, E) may not be ideal given its potential association with ILD\n\nThe answer is (B)"}]